By Sheri Kasprzak
New York, Sept. 12 - Nektar Therapeutics Inc. revealed the details of its previously announced $7,999,984 direct placement with Mansfield Enterprises, Inc.
Mansfield bought 454,803 shares at $17.59 each as part of a previously negotiated option. The company's last reported stock price was $19.59 on Sept. 9.
The shares were sold under Nektar's shelf registration.
Reedland Capital Partners was the placement agent for the offering.
Separately, Nektar sold 1,436,266 shares to Mansfield on Aug. 15 for proceeds of $24 million.
Based in San Carlos, Calif., Nektar develops drug-delivery technologies used by biotechnology and pharmaceutical companies.
| Issuer: | Nektar Therapeutics Inc.
|
| Issue: | Stock
|
| Amount: | $7,999,984
|
| Shares: | 454,803
|
| Price: | $17.59
|
| Warrants: | No
|
| Investor: | Mansfield Enterprises, Inc.
|
| Placement agent: | Reedland Capital Partners
|
| Settlement date: | Sept. 12
|
| Stock price: | $19.59 at close Sept. 9
|
| Stock price: | $18.75 at close Sept. 12
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
